TIDMIXI
IXICO plc
05 November 2019
5 November 2019
IXICO plc
("IXICO" or the "Company")
IXICO to Present Abstracts at Upcoming Huntington's Disease and
Ataxia Conferences
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, today announces that it is scheduled to
attend and present scientific posters at the following conferences
in November 2019.
The Huntington Study Group 2019 Annual Meeting
7 - 9 November 2019, Sacramento, California, USA
IXICO will present a poster entitled "A Fully Automatic Pipeline
for Estimation of Putamen and Caudate Volume" on 7 November at 5pm
and on 8 November at 3.15pm.
The abstract outlines a method for fully automated segmentation
of the caudate and putamen brain structures using IXICO's
proprietary LEAP(TM) algorithm technology as applied to a
Huntington disease cohort.
In addition, IXICO is supporting the event as 'Friends of HSG'
and the company's biomarker scientist, Dr Kirsi Kinnunen, will be
participating in the 'Ask the Expert' panel for the HSG Family Day
on Saturday 9th November.
International Ataxia Research Conference 2019
14 - 16 November 2019, Washington DC, USA
IXICO will present an abstract entitled "Fully automated
measurement of brainstem and cerebellar volume: imaging endpoint
for Ataxia, PSP and FA in multicenterclinical trial studies" on 14
November at 5.30pm and on 15 November at 12.30pm in Exhibit Hall
A.
The abstract describes the scientific validation of a
fully-automated volumetric assessment of cerebellar and brainstem
regions as well as operational considerations for successful
deployment in clinical trials.
Giulio Cerroni, Chief Executive Officer of IXICO commented: "We
are delighted to be presenting abstracts on some of our pioneering
data analytics at these upcoming conferences. As new therapies for
neurodegenerative diseases enter clinical development, the
improvement and validation of image analysis pipelines using AI
technologies, such as LEAP(TM), can critically support trial design
and clinical investigation."
Poster authors:
HSG: Richard Joules(1) , Helen Crawford(1) , Robin Wolz(1) , (2)
1) IXICO plc, London, UK 2) Imperial College London, London, UK
IARC: Abaei M(1) *, Joules R(1) , Palombit A(1) , Faber J(2) ,
(3) , Klockgether T(2) , (3) , Wolz R(1) , (4)
1) IXICO Plc, London, UK, 2) DZNE, German Center for
Neurodegenerative Diseases, Bonn Germany, 3) Department of
Neurology, University Hospital Bonn, Germany4 Department of
Computing, Imperial College London, London, UK, *Presenting
author
For further information please contact:
IXICO plc +44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
Optimum Strategic Communications +44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Charlotte
Hepburne-Scott
IXICO@optimumcomms.com
About IXICO
IXICO's purpose is to advance medicine and human health by
turning data into clinically meaningful information, providing
valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of AI in
clinical development, to improve biopharma R&D productivity
through the adoption of breakthrough data analytics in precision
healthcare. Through the deployment of novel AI algorithms, we
analyse and interpret brain scans and digital biosensor data to
enable better trial design, patient selection and ultimately
clinical outcomes across all phases of clinical evaluation. Our
data analytics services are deployed on some of the most important
clinical trials in neuroscience and rare disease, providing
valuable insights to disease progression and patient safety,
enabling our clients to make better informed decisions earlier in
the clinical development pathway.
More information is available on www.IXICO.com
About HSG Annual Meeting 2019
Since 1993, the Huntington Study Group (HSG) has hosted an
annual, internationally recognized forum for training and education
of Huntington disease (HD) researchers and for presentation of new
research findings and treatments to the worldwide community. The
event brings together more than 600 of the world's leading
Huntington disease researchers, health care providers, industry
representatives, and members of the HD community, providing an
opportunity for researchers to share abstracts of their efforts to
help improve the lives for people affected by Huntington
disease.
About IARC 2019
The International Ataxia Research Conference (IARC) provides a
comprehensive scientific review of new research into ataxias,
covering topics from the molecular basis of disease to potential
therapeutic treatments and clinical trials. The conference includes
Friedreich's ataxia and other recessive ataxias (e.g. ataxia with
oculomotor apraxia), dominant ataxias (e.g. spinocerebellar
ataxias, DRPLA, episodic ataxias) and autoimmune ataxias. The
meeting is aimed at academic, clinical and industry researchers
with an interest in ataxia research and drug development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAZZLFBKFFLFBL
(END) Dow Jones Newswires
November 05, 2019 04:00 ET (09:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024